Dr Bo Kara | Head Process Development
GlaxoSmithKline

Dr Bo Kara, Head Process Development, GlaxoSmithKline

Bo Kara heads up the Process Development team for Advanced Therapy Delivery at GSK. He has over 25 years’ experience in designing research and development programmes to develop scaleable and validatable manufacturing processes for recombinant protein products. He has published widely and is primary inventor on a range of process/expression patents. He has developed a keen understanding of the technical, regulatory and commercial issues faced at each stage of the development of manufacturing processes for biopharmaceuticals.
 
Bo Kara will be discussing manufacturing ex-vivo cell & gene therapy for rare disease and oncology applications, expression and manufacturing platforms for lentivirus production and CAR-T, upscaling to improve patient access and attepting to answer the question what does the future hold for this area of manufacturing?

Appearances:



Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 14:50

Bringing the cost of vector manufacture down to tackle the bottleneck of commercial scale autologous manufacture

  • What progresses have been made in vector manufacture?
  • Bringing the cost of vector manufacturing down to improve autologous cell manufacturing
  • What steps need to be taken to make T-Cell processing fully commercially viable

back to speakers

 

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com